Physician profile
Kenneth R Ackerman
NPI 1033205265
$7,019.05
in general payments reported to CMS, 2019-2025
35 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $556 · 2021: $1,127 · 2022: $1,307 · 2023: $968 · 2024: $1,143 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.59 | 2021-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,089.20 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $676.98 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $481.21 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $399.81 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $381.08 | 2021-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $369.94 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $298.36 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $272.42 | 2019-2025 | Prolia, Evenity, Krystexxa |
| Biohaven Pharmaceuticals, INC. | $218.06 | 2021 | |
| Lilly USA, LLC | $197.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.66 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $152.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $127.24 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $122.28 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $79.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $79.58 | 2024-2025 | |
| Horizon Therapeutics Plc | $60.84 | 2019-2022 | |
| Astellas Pharma US INC | $60.61 | 2024-2025 | Veozah |
| Abbott Laboratories | $45.69 | 2019-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $38.97 | 2019 | |
| Dynavax Technologies Corporation | $36.14 | 2021-2024 | Heplisav-B |
| Allergan, INC. | $26.97 | 2020 | |
| Sanofi-Aventis U.S. LLC | $26.11 | 2025 | |
| Renalytix Ai, INC. | $23.85 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Dermira, INC. | $23.76 | 2020 | |
| Jazz Pharmaceuticals INC. | $21.31 | 2021 | |
| Esperion Therapeutics, INC. | $20.75 | 2024 | Nexletol |
| Hikma Pharmaceuticals USA | $19.01 | 2023 | Kloxxado, Ryaltris, Mitigare |
| Althera Pharmaceuticals LLC | $18.72 | 2021 | |
| Almatica Pharma LLC | $18.16 | 2025 | Loreev Xr |
| Exact Sciences Corporation | $18.16 | 2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $18.04 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $15.54 | 2021 | |
| Acerus Pharmaceuticals Corporation | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.